West Virginia Lottery results: See winning numbers for Powerball, Lotto America on May 31, 2025
West Virginia Lottery results: See winning numbers for Powerball, Lotto America on May 31, 2025
Are you looking to win big? The West Virginia Lottery offers a variety of games if you think it's your lucky day.
Lottery players in West Virginia can choose from popular national games like the Powerball and Mega Millions, which are available in the vast majority of states. Other games include Lotto America, Daily 3, Daily 4 and Cash 25.
Big lottery wins around the U.S. include a lucky lottery ticketholder in California who won a $1.27 billion Mega Millions jackpot in December 2024. See more big winners here. And if you do end up cashing a jackpot, here's what experts say to do first.
Here's a look at Saturday, May 31, 2025 results for each game:
Winning Powerball numbers from May 31 drawing
01-29-37-56-68, Powerball: 13, Power Play: 2
Check Powerball payouts and previous drawings here.
Winning Lotto America numbers from May 31 drawing
05-11-23-40-47, Star Ball: 10, ASB: 02
Check Lotto America payouts and previous drawings here.
Winning Daily 3 numbers from May 31 drawing
7-7-0
Check Daily 3 payouts and previous drawings here.
Winning Daily 4 numbers from May 31 drawing
0-3-7-5
Check Daily 4 payouts and previous drawings here.
Feeling lucky? Explore the latest lottery news & results
When are the West Virginia Lottery drawings held?
Powerball: 11 p.m. ET on Monday, Wednesday and Saturday.
Mega Millions: 10:59 p.m. ET Tuesday and Friday.
Lotto America: 10:15 p.m. ET on Monday, Wednesday and Saturday.
Daily 3, 4: 6:59 p.m. ET Monday through Saturday.
Cash 25: 6:59 p.m. ET Monday, Tuesday, Thursday, and Friday.
Winning lottery numbers are sponsored by Jackpocket, the official digital lottery courier of the USA TODAY Network.
Where can you buy lottery tickets?
Tickets can be purchased in person at gas stations, convenience stores and grocery stores. Some airport terminals may also sell lottery tickets.
You can also order tickets online through Jackpocket, the official digital lottery courier of the USA TODAY Network, in these U.S. states and territories: Arizona, Arkansas, Colorado, Idaho, Maine, Massachusetts, Minnesota, Montana, Nebraska, New Hampshire, New Jersey, New York, Ohio, Oregon, Puerto Rico, Washington D.C., and West Virginia. The Jackpocket app allows you to pick your lottery game and numbers, place your order, see your ticket and collect your winnings all using your phone or home computer.
Jackpocket is the official digital lottery courier of the USA TODAY Network. Gannett may earn revenue for audience referrals to Jackpocket services. GAMBLING PROBLEM? CALL 1-800-GAMBLER, Call 877-8-HOPENY/text HOPENY (467369) (NY). 18+ (19+ in NE, 21+ in AZ). Physically present where Jackpocket operates. Jackpocket is not affiliated with any State Lottery. Eligibility Restrictions apply. Void where prohibited. Terms: jackpocket.com/tos.
This results page was generated automatically using information from TinBu and a template written and reviewed by a USA Today editor. You can send feedback using this form.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
Hudson Market Basket sells $2M winning Powerball ticket
A winning Powerball ticket worth $2 million was purchased at Market Basket on Lowell Road in Hudson for the May 31 drawing. The ticket, originally a $1 million winner, was doubled by a Power Play multiplier, resulting in a $2 million jackpot win. 'Another big Powerball winner in New Hampshire! What an exciting time for us here at the New Hampshire Lottery,' said Charlie McIntyre, Executive Director, New Hampshire Lottery. 'Congratulations to Market Basket in Hudson for the sale, and to our big winner. We'll be eagerly awaiting your arrival at Lottery headquarters to hand over that big prize. The only question that remains is who's next?' The winning numbers from the Powerball drawing on Saturday, May 31, were: 01-29-37-56-68 PB-13. This lucky winner follows a $1 million Powerball winning ticket sold at Hannaford in Rochester for the May 21 drawing. The $204.5 million Powerball jackpot was won in California for the May 31 drawing.
Yahoo
2 hours ago
- Yahoo
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
– CR/CRh rate of 23% in pivotal Ph 2 cohort of R/R NPM1-m AML patients – – Consistent efficacy with comparable CR/CRh rates and clinically meaningful MRD-negative responses across pre-specified subgroups, regardless of prior HSCT, prior venetoclax, or FLT3/IDH co-mutations – – Favorable safety and tolerability profile in heavily pre-treated patients: limited myelosuppression; no clinically meaningful QTc prolongation; 3% of patients discontinued due to treatment-related adverse events – – Potential first approval of a once-daily, oral menin inhibitor for treatment of adult patients with relapsed or refractory NPM1-mutated AML with Priority Review and a PDUFA target action date of November 30, 2025 – – Kura Oncology to host virtual investor event today at 7:30pm ET / 4:30pm PT – SAN DIEGO and TOKYO, June 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, 'Kura') and Kyowa Kirin Co., Ltd. (TSE: 4151, 'Kyowa Kirin') announced the presentation of positive pivotal results from the KOMET-001 Phase 2 registration-directed trial of ziftomenib, a once-daily, oral investigational menin inhibitor, in patients with relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML) in an oral session today at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago, IL from May 30 - June 3, 2025. "We are delighted to announce positive pivotal data from the KOMET-001 trial in R/R NPM1-mutated AML patients treated with ziftomenib," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "NPM1 mutations are among the most common in AML, representing approximately 30% of cases, and there are no FDA-approved therapies specifically for this patient population. With these encouraging results and a PDUFA target action date of November 30, 2025, we and our partners at Kyowa Kirin look forward to supporting FDA with its review of the ziftomenib New Drug Application (NDA) and are well-positioned to meaningfully impact relapsed or refractory patients with NPM1 mutations.' "Relapsed or refractory NPM1-mutated AML is a highly challenging disease with a poor prognosis and an urgent need for new treatments," said Eunice Wang, M.D., Chief of Leukemia Service, Professor of Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY. "The promising results for ziftomenib in this heavily pretreated population are highly encouraging. Notably, the clinically meaningful minimal residual disease (MRD)-negative responses observed as well as the similar response rates seen regardless of prior therapies, including hematopoietic stem cell transplantation (HSCT) and venetoclax, hold great promise for the potential use of ziftomenib in patients with relapsed and refractory NPM1-mutated AML.' The KOMET-001 Phase 2 population included 92 adult patients with R/R NPM1-m AML. The median age was 69 (range: 33 to 84). Patients were heavily pretreated, with 33% having received three or more prior lines of therapy (median prior lines: 2) and 59% having been previously treated with venetoclax. A complete remission (CR) plus CR with partial hematological recovery (CRh) rate of 23% (21/92) was observed among patients with R/R NPM1-m AML in the Phase 2 portion of the KOMET-001 trial. Among those 21 patients who achieved CR/CRh, 13 had a CR and 8 had a CRh. The median duration of CR/CRh responses was 3.7 months (95% CI: 1.9, not estimable (NE)) and the restricted mean duration of response was 4.3 months (95% CI: 3.1, 5.6) at the time of the data cutoff. MRD status was assessed in 19 of 21 patients who achieved CR/CRh, and 63% (12/19) of these patients were MRD-negative. Comparable CR/CRh rates were observed across pre-specified subgroups, regardless of prior HSCT, prior venetoclax or FLT3/IDH co-mutations. Additional patient benefit beyond CR/CRh was observed with a rate of transfusion conversion of 21% (17/82; 95% CI: 13-31) and a rate of maintenance of transfusion independence of 20% (2/10; 95% CI: 3-56). A median OS of 16.4 months (95% CI, 9.6–20.4) was observed for responders (patients who achieved CR, CRh, CRi/CRp, MLFS or PR) and a median overall survival (OS) of 3.5 months (95% CI, 2.5–4.0) was observed among non-responders. The safety population included 112 adult patients with R/R NPM1-m AML from the pooled Phase 1b and Phase 2 portions of the KOMET-001 trial. The safety profile observed with ziftomenib in this population was consistent with previously reported data. Treatment-related adverse events (TRAEs) led to treatment discontinuations in 3% of patients. TRAEs of Grade ≥3 which occurred in more than 10% of patients were limited to differentiation syndrome (DS, 13%), which was well managed by protocol-specified mitigation strategies and no Grade 4/5 treatment-related DS was observed. Although QTc prolongation (1 Gr2; 2 Gr3) was reported in three patients per investigator assessment, all three patients were on concomitant medications associated with QTc prolongation, two had electrolyte abnormalities and one had a prior diagnosis of atrial fibrillation. 'Beyond ziftomenib's clinical activity, we are highly encouraged by its consistent safety and tolerability profile,' said Mollie Leoni, MD, Chief Medical Officer of Kura Oncology. 'Notably, the low rate of myelosuppression, low discontinuation rate, lack of clinically significant QTc prolongation, absence of drug-drug interactions, and effective management of differentiation syndrome underscore ziftomenib's potentially favorable benefit-risk profile for patients with relapsed or refractory NPM1-mutated AML.' 'The data presented at ASCO strengthen our conviction that ziftomenib has potential to become a meaningful treatment option for patients with relapsed or refractory AML with NPM1 mutations — patients who often face limited treatment options and significant uncertainty regarding their prognosis,' said Takeyoshi Yamashita, Ph.D., Executive Vice President and Chief Medical Officer of Kyowa Kirin. 'Encouraged by the favorable safety, tolerability, and promising clinical activity observed thus far, Kyowa Kirin, in collaboration with Kura, is working with urgency and purpose to bring ziftomenib monotherapy to patients as swiftly and responsibly as possible.' Virtual Investor Event Kura will host a virtual investor event featuring company management and investigators from the KOMET-001 trial of ziftomenib in R/R NPM1-m AML at 7:30pm ET / 4:30pm PT on Monday, June 2, 2025. Those who would like to participate may access the live webcast here, or register in advance for the teleconference event can also be accessed on the Investors section of Kura's website at An archived replay will be available shortly after the conclusion of the live event. About Kura Oncology Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company's pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the FDA for the treatment of R/R NPM1-m AML. In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in KOMET-001, a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-m AML, has been completed, and the companies announced submission of an NDA for ziftomenib for the treatment of adult patients with R/R NPM1-m AML in the first quarter of 2025. Kura and Kyowa Kirin are conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-m and KMT2A-rearranged AML. Ziftomenib is also being evaluated in a Phase1 dose-escalation trial (KOMET-015) in combination with imatinib for treatment of patients with advanced GIST. KO-2806, a next-generation farnesyl transferase inhibitor (FTI), is being evaluated in a Phase 1 dose-escalation trial (FIT-001) as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective FTI, is currently in a Phase 1/2 trial (KURRENT-HN) in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura's website at and follow us on X and LinkedIn. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel medicines and treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, Kyowa Kirin has invested in drug discovery and biotechnology innovation for more than 70 years and is currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, such as bone & mineral, intractable hematological diseases/hemato-oncology and rare diseases. A shared commitment to Kyowa Kirin's values, to sustainable growth, and to making people smile unites Kyowa Kirin across the globe. You can learn more about the business of Kyowa Kirin at Kura Forward-Looking Statements This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, the efficacy, safety and therapeutic potential of ziftomenib; interactions with the FDA relating to our NDA for ziftomenib; the anticipated timing of FDA approval of our NDA and the potential to benefit patients with R/R NPM1-m AML. Factors that may cause actual results to differ materially include the risk that compounds that appeared promising in early research or clinical trials do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Kura may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings, and other interactions with regulatory bodies, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, the risk that the collaboration with Kyowa Kirin is unsuccessful, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words 'may,' 'will,' 'would,' 'could,' 'should,' 'believes,' 'estimates,' 'projects,' 'promise,' 'potential,' 'expects,' 'plans,' 'anticipates,' 'intends,' 'continues,' 'designed,' 'goal,' or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties the Company faces, please refer to the Company's periodic and other filings with the Securities and Exchange Commission, which are available at Such forward-looking statements are current only as of the date they are made, and Kura assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. Kura Contacts Investors: Patti Bank Managing Director(415) Media:media@ Kyowa Kirin Contacts Investors: Ryohei Kawaiir@ Media, Global:Wataru Suzuki, media@ in to access your portfolio
Yahoo
2 hours ago
- Yahoo
Judge orders Texas Lottery Commission to protect $83.5 million of disputed funds won in February jackpot
AUSTIN (Nexstar) — A Travis County judge issued a temporary restraining order against the Texas Lottery Commission (TLC) and its acting executive director from spending any of the $83.5 million a Houston woman won in a February Lotto Texas jackpot. None of the jackpot has been paid out because the Texas Rangers are currently investigating the win — along with an April 2023 jackpot win — to see if there was any foul play involved. The judge wrote in the ruling that the Texas woman 'will be irreparably harmed if Defendant Sergio Rey, in his official capacity as acting executive director for the Texas Lottery Commission causes the $83,500,000 jackpot prize to be diminished, wasted, or paid to another before the merits of Plaintiff's claims are fully and finally adjudicated.' The ruling comes the same day a bill to end the TLC was sent to the Governor's desk for final approval. Senate Bill 3070 would eliminate the commission and transfer the operation of the lottery and charitable bingo to the Texas Department of Licensing and Regulation (TDLR). Temporary Restraining Order against TLCDownload Randy Howry, the lottery winner's attorney, said he believes the restraining order will also apply to the TDLR if the Governor signs the bill into law. The restraining order has a limited lifespan. In this case it will only last three days because there is an evidentiary hearing on June 5 for a temporary injunction. A temporary injunction would protect those funds until a trial can happen. Howry and his client are worried the February lottery winnings could be spent on other winners or pay for other costs within the commission as it faces extinction. 'We're doing everything we can to protect these funds,' Howry explained. The Texas woman won the Feb. 17 lottery drawing worth $83.5 million. The woman purchased $20 worth of tickets on the Jackpocket app, a service that allows players to buy tickets over the phone. Those services are known as lottery couriers and they have become the target of lawmakers this session who believe they are against the laws written in the state and believe the lottery commission acted beyond its means to allow couriers to operate in Texas. Some lottery courier services were involved in helping a single entity, known as Rook TX, purchase and print more than $25 million worth of tickets in a 72-hour time span in April of 2023. That number of tickets nearly guaranteed the entity would have the winning ticket for a $95 million jackpot. This session lawmakers have questioned the TLC and its commissioners about how something like that could happen. Lawsuits have been filed against those courier services and the former executive director of the commission. In February, a week after the Texas woman won the jackpot, the TLC said it was banning lottery courier services and the Governor directed the Texas Rangers to investigate those two wins. Howry said he and his client were told by the commission they could not be paid out while the Rangers investigated. However, Howry says he and his client have not been questioned by any agency regarding the February drawing. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
